|
|
 |
|
Viewing report
|
|
|
|
Therapeutics Targeting ERB Family
Panel Intelligence, LLC, Dec 2000, Pages: 59
This report details the market intelligence gathered in this project and elucidates the impressions of thought leader experts regarding the future of Egfr therapies. The physicians reported interest in using Egfr therapeutics to help increase normal growth of diseased or damaged tissues and to inhibit aberrant growth in the form of malignancies.
The malignancies reported to be most commonly associated with disrupted Egfr signaling include breast, colon, head and neck, lung, and ovarian. Other diseases that may be associated with altered Egfr signaling include granulomatous diseases such as sarcoid and inflammatory diseases like psoriasis.
The panel was generally enthusiastic about the future of Egfr research since the side effects of these agents appear minimal and the efficacy appears promising. A lively discussion also compared tyrosine kinase inhibitors with Egfr monoclonal antibodies.
The report includes keynote speaker summaries, executive summaries of the discussion, snapshots of two targeted therapeutics, and full transcripts of the entire discussion.
Customers who bought this item also bought
Li & Fung Limited
LI Ning Company Limited
Li-ion Battery & Li-ion Battery Raw Materials Market Report, 2007
Li-ion Battery & Li-ion Battery Raw Materials Market Report, 2007
United U-Li Corporation Berhad
Li Peng Enterprise Company Limited
Jui Li Enterprise Co Ltd
Li Cheng Enterprise Co.,Ltd.
China's Power Li-ion Battery Market Report 2008
China Li-ion Battery & Its Raw Materials Market Report, 2007-2008
China Li-ion Battery & Its Raw Materials Market Report, 2007-2008
China li norit solar energy water heater market analysis
|
|
|
|
